63 related articles for article (PubMed ID: 6452881)
21. Alleviation of motor hyperactivity and neurochemical deficits by endocannabinoid uptake inhibition in a rat model of Huntington's disease.
Lastres-Becker I; Hansen HH; Berrendero F; De Miguel R; Pérez-Rosado A; Manzanares J; Ramos JA; Fernández-Ruiz J
Synapse; 2002 Apr; 44(1):23-35. PubMed ID: 11842443
[TBL] [Abstract][Full Text] [Related]
22. Huntington's chorea and bromocriptine.
Albano C; Cocito L
Arch Neurol; 1979 May; 36(5):322. PubMed ID: 156018
[No Abstract] [Full Text] [Related]
23. Animal models of Huntington's disease.
Gárdián G
Ideggyogy Sz; 2006 Nov; 59(11-12):396-9. PubMed ID: 17203874
[TBL] [Abstract][Full Text] [Related]
24. Adenosine A2A receptor blockade before striatal excitotoxic lesions prevents long term behavioural disturbances in the quinolinic rat model of Huntington's disease.
Scattoni ML; Valanzano A; Pezzola A; March ZD; Fusco FR; Popoli P; Calamandrei G
Behav Brain Res; 2007 Jan; 176(2):216-21. PubMed ID: 17123640
[TBL] [Abstract][Full Text] [Related]
25. [On age-dependent effects of IDPN in the rat (author's transl)].
Schneider G; Oepen H; Klapproth A
Z Alternsforsch; 1980; 35(3):231-7. PubMed ID: 7456507
[TBL] [Abstract][Full Text] [Related]
26. Growth hormone and prolactin release in Huntington's chorea.
Chalmers RJ; Johnson RH; Nanda RN
Lancet; 1977 Oct; 2(8042):824. PubMed ID: 71631
[No Abstract] [Full Text] [Related]
27. Clonazepam in the treatment of choreiform activity.
Peiris JB; Boralessa H; Lionel ND
Med J Aust; 1976 Feb; 1(8):225-7. PubMed ID: 131236
[TBL] [Abstract][Full Text] [Related]
28. Huntington's Chorea and dimethylaminoethanol (deanol).
Amsterdam JD; Dubin W
J Clin Psychiatry; 1978 Jul; 39(7):626-8. PubMed ID: 150413
[TBL] [Abstract][Full Text] [Related]
29. [Model of choreic movement in monkey--contribution for understanding the mechanism of chorea in Huntington's disease].
Kanazawa I
Jikken Dobutsu; 1990 Apr; 39(2):168-72. PubMed ID: 2141819
[No Abstract] [Full Text] [Related]
30. Protective effect of hesperidin and naringin against 3-nitropropionic acid induced Huntington's like symptoms in rats: possible role of nitric oxide.
Kumar P; Kumar A
Behav Brain Res; 2010 Jan; 206(1):38-46. PubMed ID: 19716383
[TBL] [Abstract][Full Text] [Related]
31. The IGF-I amino-terminal tripeptide glycine-proline-glutamate (GPE) is neuroprotective to striatum in the quinolinic acid lesion animal model of Huntington's disease.
Alexi T; Hughes PE; van Roon-Mom WM; Faull RL; Williams CE; Clark RG; Gluckman PD
Exp Neurol; 1999 Sep; 159(1):84-97. PubMed ID: 10486177
[TBL] [Abstract][Full Text] [Related]
32. Possible neuroprotective effect of Withania somnifera root extract against 3-nitropropionic acid-induced behavioral, biochemical, and mitochondrial dysfunction in an animal model of Huntington's disease.
Kumar P; Kumar A
J Med Food; 2009 Jun; 12(3):591-600. PubMed ID: 19627208
[TBL] [Abstract][Full Text] [Related]
33. [Therapy of Huntington's chorea: a pharmacological and clinical approach to the organization of the basal ganglia].
Roccatagliata G; Albano C
Clin Ter; 1980 Aug; 94(3):249-56. PubMed ID: 6450021
[No Abstract] [Full Text] [Related]
34. Sub-chronic copper pretreatment reduces oxidative damage in an experimental Huntington's disease model.
Martínez-Lazcano JC; Montes S; Sánchez-Mendoza MA; Rodríguez-Páez L; Pérez-Neri I; Boll MC; Campos-Arroyo HD; Ríos C; Pérez-Severiano F
Biol Trace Elem Res; 2014 Dec; 162(1-3):211-8. PubMed ID: 25319005
[TBL] [Abstract][Full Text] [Related]
35. Exendin-4 improves glycemic control, ameliorates brain and pancreatic pathologies, and extends survival in a mouse model of Huntington's disease.
Martin B; Golden E; Carlson OD; Pistell P; Zhou J; Kim W; Frank BP; Thomas S; Chadwick WA; Greig NH; Bates GP; Sathasivam K; Bernier M; Maudsley S; Mattson MP; Egan JM
Diabetes; 2009 Feb; 58(2):318-28. PubMed ID: 18984744
[TBL] [Abstract][Full Text] [Related]
36. A pharmacologic model of Huntington's chorea.
Dill RE; Dorris RL; Phillips-Thonnard I
J Pharm Pharmacol; 1976 Aug; 28(8):646-8. PubMed ID: 11317
[No Abstract] [Full Text] [Related]
37. Adaptation of the growing lung to increased VO2. I. IDPN as inducer of hyperactivity.
Burri PH; Gehr P; Müller K; Weibel ER
Respir Physiol; 1976 Oct; 28(1):129-40. PubMed ID: 988630
[TBL] [Abstract][Full Text] [Related]
38. Glucosamine dependence of Huntington's chorea fibroblasts in culture.
Tourian A; Hung W
Biochem Biophys Res Commun; 1976 May; 76(2):345-53. PubMed ID: 141285
[No Abstract] [Full Text] [Related]
39. Huntington chorea.
Tolosa ES; Sparber SB
Arch Neurol; 1977 Jan; 34(1):58-9. PubMed ID: 137702
[No Abstract] [Full Text] [Related]
40. Pentobarbitone anaesthesia in an animal model of huntington's disease.
Sanberg PR; Pisa M; Fibiger HC
Br J Anaesth; 1981 Apr; 53(4):442. PubMed ID: 6452890
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
